natgillin/translations-raw huggingface dataset:
It works by blocking an enzyme called cyclo-oxygenase, which produces prostaglandins, substances that are involved in the inflammation process. 
Deluje tako, da zavira encim, imenovan ciklooksigenaza, ki tvori prostaglandine, snovi, vpletene v vnetni proces.
Three main studies in patients were carried out, comparing Beprana with naproxen (another medicine used in osteoarthritis) and placebo (a dummy treatment). 
Izvedene so bile tri glavne študije, v katerih so zdravilo Beprana primerjali z naproksenom (drugim zdravilom, ki se uporablja pri osteoartritisu) in placebom (zdravilom brez zdravilne učinkovine).
Based on the review of the data and the company's response to the CHMP lists of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Beprana could not have been approved for the relief of signs and symptoms of osteoarthritis of the knee and hip. 
Na podlagi pregleda podatkov in odgovorov družbe na sezname vprašanj, ki jih je zastavil CHMP, je Odbor v času umika izrazil določene zadržke in je začasno menil, da zdravila Beprana ni mogoče odobriti za lajšanje znakov in simptomov osteoartritisa kolena in kolka.
On 19 April 2011, NicOx S. A. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Beprana in adults for the relief of signs and symptoms of osteoarthritis of the knee and hip. 
Družba NicOx S.A. je dne 19. aprila 2011 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za pridobitev dovoljenja za promet z zdravilom Beprana, namenjenim lajšanju znakov in simptomov osteoartritisa kolena in kolka pri odraslih.
Nitric oxide is a vasodilator, a substance that causes the widening of blood vessels. 
Dušikov oksid je vazodilatator, snov, ki povzroča širjenje krvnih žil.
The active substance in Beprana, naproxcinod, is converted in the body into the drug naproxen and a chemical that releases nitric oxide. 
Zdravilna učinkovina v zdravilu Beprana, naprokscinod, se v telesu pretvori v zdravilo naproksen in kemično snov, ki sprošča dušikov oksid.
Beprana was expected to be used to relieve the signs and symptoms of osteoarthritis (swelling and pain in the joints) of the knee and hip in adults. 
Zdravilo Beprana naj bi se uporabljalo za lajšanje znakov in simptomov osteoartritisa (zatekanje in bolečine v sklepih) kolena in kolka pri odraslih.
The CHMP noted that while there was evidence showing that Beprana was effective in relieving the signs and symptoms of osteoarthritis of the knee and hip, its benefits were not sufficient to outweigh the identified risks. 
CHMP je menil, da sicer obstajajo dokazi o učinkovitosti zdravila Beprana pri lajšanju znakov in simptomov osteoartritisa kolena in kolka, vendar pa njegove koristi niso zadostne, da bi odtehtale znana tveganja.
How is Beprana expected to work? 
Kako naj bi zdravilo Beprana delovalo?
What was Beprana expected to be used for? 
Za kaj naj bi se zdravilo Beprana uporabljalo?
By reducing the production of prostaglandins, Beprana is expected to reduce the inflammation and pain seen in osteoarthritis. 
Pričakovali so, da bo zdravilo Beprana z zmanjšanjem tvorjenja prostaglandinov zmanjšalo tudi vnetje in bolečino, ki ju povzroča osteoartritis.
Beprana is a medicine that contains the active substance naproxcinod. 
Beprana je zdravilo, ki vsebuje zdravilno učinkovino naprokscinod.
It is available as capsules (1.5, 3, 4.5 and 6 mg). 
Na voljo je v obliki kapsul (1,5, 3, 4,5 in 6 mg).
The European Commission granted a marketing authorisation valid throughout the European Union for Rivastigmine Actavis on 16 June 2011. 
Evropska komisija je dovoljenje za promet z zdravilom Rivastigmine Actavis, veljavno po vsej Evropski uniji, izdala 16. junija 2011.
The full EPAR for Rivastigmine Actavis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Rivastigmine Actavis je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
This means that Rivastigmine Actavis is similar to a ‘reference medicine' already authorised in the European Union (EU) called Exelon. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Exelon.
Rivastigmine Actavis should be given twice a day, with morning and evening meals. 
Zdravilo Rivastigmine Actavis se daje dvakrat na dan ob zajtrku in večerji.
Rivastigmine Actavis rivastigmine 
Rivastigmine Actavis rivastigmin
This is a summary of the European public assessment report (EPAR) for Rivastigmine Actavis. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Rivastigmine Actavis.
For more information about treatment with Rivastigmine Actavis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Rivastigmine Actavis preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
In patients with Alzheimer's dementia or dementia due to Parkinson's disease, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a chemical that allows nerve cells to communicate with each other). 
Pri bolnikih z alzheimerjevo demenco ali demenco zaradi parkinsonove bolezni v možganih odmirajo določene živčne celice, zaradi česar se znižajo ravni živčnega prenašalca acetilholina (kemične snovi, ki omogoča medsebojno komunikacijo med živčnimi celicami).
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rivastigmine Actavis. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Treatment with Rivastigmine Actavis should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer's disease or dementia in patients with Parkinson's disease. 
Zdravljenje z zdravilom Rivastigmine Actavis mora uvesti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem alzheimerjeve bolezni ali demence pri bolnikih s parkinsonovo boleznijo.
Rivastigmine Actavis is used for the treatment of patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour. 
Zdravilo Rivastigmine Actavis se uporablja za zdravljenje bolnikov z blago do zmerno hudo alzheimerjevo demenco, tj. napredujočo okvaro možganov, ki postopoma prizadene spomin, intelektualne zmožnosti in vedenje.
Because Rivastigmine Actavis is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Rivastigmine Actavis generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
What are the benefits and risks of Rivastigmine Actavis? 
Kakšne so koristi in tveganja, povezani z zdravilom Rivastigmine Actavis ?
It can also be used to treat mild to moderately severe dementia in patients with Parkinson's disease. 
Zdravilo se lahko uporablja tudi za zdravljenje blage do zmerno hude demence pri bolnikih s parkinsonovo boleznijo.
Treatment should only be started if a caregiver is available who will regularly monitor the use of Rivastigmine Actavis by the patient. 
Zdravljenje se lahko začne samo ob prisotnosti negovalca, ki redno nadzoruje uporabo zdravila Rivastigmine Actavis pri bolniku.
Rivastigmine Actavis is a ‘generic medicine'. 
Rivastigmine Actavis je „generično zdravilo“.
In patients who tolerate this dose, it can be increased in 1.5 mg steps no more frequently than every two weeks, to a regular dose of 3 to 6 mg twice a day. 
Pri bolnikih, ki prenašajo navedeni odmerek, se lahko ta postopoma povečuje za 1,5 mg, vendar ne pogosteje kot vsaka dva tedna, dokler se ne doseže stalni odmerek 3 do 6 mg dvakrat na dan. Za doseg največje učinkovitosti se uporabi največji odmerek, ki ga bolnik še prenaša, vendar ta ne sme preseči 6 mg dvakrat na dan.
The Committee recommended that Rivastigmine Actavis be given marketing authorisation. 
Priporočil je, da se za zdravilo Rivastigmine Actavis izda dovoljenje za promet.
Rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase. 
Rivastigmin deluje tako, da zavira encima, ki razgrajujeta acetilholin: acetilholinesterazo and butirilholinesterazo.
Other information about Rivastigmine Actavis 
Druge informacije o zdravilu Rivastigmine Actavis
By blocking these enzymes, Rivastigmine Actavis allows levels of acetylcholine to increase in the brain, helping to reduce the symptoms of Alzheimer's dementia and dementia due to Parkinson's disease. 
Zdravilo Rivastigmine Actavis z zaviranjem teh encimov omogoča, da se ravni acetilholina v možganih povečajo, zaradi česar se simptomi alzheimerjeve demence in demence zaradi parkinsonove bolezni ublažijo.
The CHMP concluded that, in accordance with EU requirements, Rivastigmine Actavis has been shown to have comparable quality and to be bioequivalent to Exelon. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Rivastigmine Actavis primerljivo raven kakovosti kot zdravilo Exelon ter da mu je biološko enakovredno.
Rivastigmine Actavis is a medicine containing the active substance rivastigmine. 
Rivastigmine Actavis je zdravilo, ki vsebuje zdravilno učinkovino rivastigmin.
The active substance in Rivastigmine Actavis, rivastigmine, is a dementia medicine. 
Zdravilna učinkovina zdravila Rivastigmine Actavis, rivastigmin, je zdravilo proti demenci.
Because Rivastigmine Actavis is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Exelon. 
Ker je zdravilo Rivastigmine Actavis generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Exelon.
Why has Rivastigmine Actavis been approved? 
Zakaj je bilo zdravilo Rivastigmine Actavis odobreno?
What is Rivastigmine Actavis used for? 
Za kaj se zdravilo Rivastigmine Actavis uporablja?
Therefore, the CHMP's view was that, as for Exelon, the benefit outweighs the identified risk. 
Zato je menil, da koristi zdravila Rivastigmine Actavis, tako kot pri zdravilu Exelon, odtehtajo znana tveganja.
How has Rivastigmine Actavis been studied? 
Kako je bilo zdravilo Rivastigmine Actavis raziskano?
How is Rivastigmine Actavis used? 
Kako se zdravilo Rivastigmine Actavis uporablja?
What is Rivastigmine Actavis? 
Kaj je zdravilo Rivastigmine Actavis?
How does Rivastigmine Actavis work? 
Kako zdravilo Rivastigmine Activis deluje?
The Member States should ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below are implemented: 
Države članice morajo zagotoviti, da bodo uveljavljeni vsi spodaj opisani pogoji oziroma omejitve v zvezi z varno in učinkovito uporabo zdravila.
• Velcade 3.5mg can be administered both intravenously and subcutaneously while Velcade 1mg can be administered only intravenously 
• Zdravilo VELCADE 3,5 mg se lahko daje intravensko in subkutano, zdravilo VELCADE 1 mg pa samo intravensko.
Prior to launch of Velcade 3.5mg new dual route of administration (subcutaneous and intravenous) package, in each Member State, the Marketing Authorisation Holder (MAH) shall agree the content and format of the educational material with the national competent authority. 
Imetnik dovoljenja za promet z zdravilom se bo pred začetkom trženja novega, dvojnega načina uporabe zdravila VELCADE 3,5 mg (subkutana in intravenska uporaba), v vsaki državi članici s pristojnim nacionalnim organom države dogovoril za obliko in vsebino izobraževalnih gradiv za zdravstvene delavce.
• potential risks of administration errors including overdosing, underdosing and that inadvertent intrathecal administration has resulted in death 
• Možna tveganja napak pri dajanju zdravila, vključno z informacijami o prevelikem odmerjanju,
• SmPC 
ali subkutani (s.c.)
The MAH shall ensure that, at launch of Velcade 3.5mg new dual route package and thereafter, all healthcare professionals involved in the prescribing, dispensing, handling or administration of Velcade 3.5mg are provided with educational material. 
Imetnik dovoljenja za promet z zdravilom bo ob začetku trženja novega, dvojnega načina uporabe zdravila VELCADE 3,5 mg in še naprej zagotovil, da bodo vsi zdravstveni delavci, ki bodo predpisovali ali uporabljali zdravilo prejeli izobraževalno gradivo.
• that Velcade 1mg is only for IV use 
• Zdravilo VELCADE 1 mg se lahko uporablja samo intravensko.
• dosing instructions and examples: how to calculate the body surface area of a patient and the volume of reconstituted Velcade (both IV and SC use) required for different body surface areas. 
• Navodila za odmerjanje s primeri: kako se izračuna telesna površina bolnika in volumen rekonstituiranega zdravila VELCADE (za i.v.
• a dose-calculation tool that enables prescribers to input a patient's height and weight in order to calculate the body surface area (BSA) and thereby to determine the appropriate VELCADE dose. 
Navodila za odmerjanje zdravila morajo vsebovati naslednje ključne elemente: odel izračuna, s katerim bo lahko predpisovalec izračunal odmerek zdravila in telesno površino na podlagi bolnikove višine in telesne mase, in tako določil pravi odmerek zdravila VELCADE.
• that Velcade is to be given only by IV or SC injections; no other route of administration is allowed 
ali s.c., nobena druga uporaba ni dovoljena.
It is a pleasure for me, at this point, to congratulate him and wish him every success in his further term of office. 
V veliko zadovoljstvo mi je, da mu ob tej priložnosti čestitam in zaželim veliko uspeha v novem mandatu.
On behalf of the Management Board, I would like to emphasise a couple of events that took place last year. 
V imenu upravnega odbora bi rad izpostavil nekaj dogodkov, ki so se zgodili v lanskem letu.
This close-knit network has been strengthened in recent years. 
Ta tesno prepletena mreža se je v zadnjih letih okrepila.
1 IMPLEMENTATION OF THE REVISED LEGISLATION 
1 IZVAJANJE REVIDIRANE ZAKONODAJE
7 SUPPORT TO SMALL AND MEDIUM-SIZED ENTERPRISES 
7 PODPORA MALIM IN SREDNJE VELIKIM PODJETJEM
In addition to these notifications, the Agency received over 1,000 notifications of changes. 
Agencija je poleg teh obvestil prejela tudi več kot 1000 obvestil o spremembah.
There were no negative opinions. 
Negativnih mnenj ni bilo.
This number includes reports originating in the EU and in countries outside the EU, such as the United States. 
Ta številka vključuje poročila, ki izvirajo iz EU in držav zunaj EU, kot na primer Združenih držav Amerike.
The evaluation period for the pandemic variation is then expected to be very short, typically less than one week. 
Obdobje vrednotenja variacije pandemije naj bi bilo tako zelo kratko, navadno manj kot en teden.
This has been achieved by rationalisation of human resources and further process automation. 
To je bilo doseženo z racionalizacijo človeških virov in nadaljnjo avtomatizacijo procesa.
An initial prototype was demonstrated to the responsible implementation group in December. 
Začetni prototip je bil decembra predstavljen odgovorni izvedbeni skupini.
This initiative runs in parallel to a similar one initiated by Member States through the Mutual Recognition Facilitation Group. 
Ta pobuda poteka vzporedno s podobno pobudo, ki so jo sprožile države članice prek skupine za poenostavitev medsebojnega priznavanja (Mutual Recognition Facilitation Group).
12 COORDINATION GROUPS FOR THE MUTUAL RECOGNITION PROCEDURE AND THE DECENTRALISED PROCEDURE 
12 USKLAJEVALNI SKUPINI ZA POSTOPEK MEDSEBOJNEGA PRIZNAVANJA IN DECENTRALIZIRANI POSTOPEK
Ultimate responsibility for the Agency's operational work rests with the Executive Director. 
Končno odgovornost za operativno delo Agencije ima izvršni direktor.
Working with national competent authorities 
Sodelovanje z nacionalnimi pristojnimi organi
The full annual report 2005 in English can be found on the Agency's website: www.emea.eu.int 
Celotno letno poročilo za leto 2005 v angleškem jeziku lahko najdete na spletni strani Agencije: www.emea.eu.int
OJ L 136, 30.04.2004, p. 1. 
UL L 136, 30. 4. 2004, str. 1.
Competitiveness of the European pharmaceutical industry in the context of the ‘Lisbon Agenda' remains high on the political agenda. 
Konkurenčnost evropske farmacevtske industrije v okviru "programa lizbonske strategije" ostaja še naprej ena od prednostnih nalog politične agende.
Despite the increasing number of requests, the average issuing time has remained within procedural limits. 
Kljub naraščajočemu številu zahtevkov je povprečni čas izdaje ostal v postopkovnih mejah.
This document provides a summary of the Agency's annual report for 2005, adopted by the Management Board on 9 March 2006. 
Ta dokument je povzetek letnega poročila Agencije za leto 2005, ki ga je upravni odbor sprejel 9. marca 2006.
The EMEA provided full secretariat and administrative support to the work of the two coordination groups. 
EMEA je zagotovila polno podporo sekretariata in administrativno podporo za delo teh dveh usklajevalnih skupin.
10 CONTRIBUTION TO EU PUBLIC HEALTH STRATEGIES 
10 PRISPEVEK K STRATEGIJAM JAVNEGA ZDRAVJA EU
The scheme will only become fully operational once the guidelines on adaptation of data requirements become available. 
Program bo začel v celoti delovati, šele ko bodo na razpolago smernice o prilagoditvi podatkovnih zahtev.
Only 32 reports related to food-producing animals. 
Samo 32 poročil se je nanašalo na živali, namenjene proizvodnji hrane.
Integrated quality management system 
Integrirani sistem upravljanja kakovosti
I would also like to thank the secretariat of the Management Board for their constructive and outstanding collaboration throughout the year. 
Rad bi se zahvalil tudi članom sekretariata upravnega odbora za njihovo konstruktivno in izjemno sodelovanje skozi vso leto.
I am confident that, as a result, the broadened outlook of the Management Board will have a favourable impact on our work. 
Prepričan sem, da bodo tako povečane možnosti upravnega odbora pozitivno vplivale na naše delo.
On 20 November 2005, the Agency welcomed the full entry into force of Regulation (EC) No 726/20042, which heralds a more robust, modern and effective regulatory framework for pharmaceuticals in Europe. 
20. novembra 2005 je Agencija pozdravila začetek veljavnosti Uredbe (ES) št. 726/20041, ki uvaja bolj robusten, sodoben in učinkovit regulativni okvir za farmacevtske izdelke v Evropi.
11 PREPARATION FOR NEW TYPES OF APPLICATIONS 
11 PRIPRAVE ZA NOVE VRSTE VLOG
Achievements of particular note include: 
Med še zlasti pomembnimi dosežki naj omenimo:
These stakeholders reported electronically a total of 144,786 individual case safety reports (ICSRs) originating from within and outside the EU. 
Te zainteresirane strani so elektronsko sporočile skupno 144.786 varnostnih poročil o posameznih primerih (individual case safety reports - ICSR), ki so izvirali iz EU in zunaj nje.
Administrative and procedural assistance from the SME Office at the Agency 
administrativno in postopkovno pomoč, ki jo zagotavlja Urad za MSP pri Agenciji;
Commission Regulation (EC) No 2049/2005, OJ L329, 16.12.2005, p. 4. 
Uredba Komisije (ES) št. 2049/2005, UL L329, 16. 12. 2005, str. 4.
The Agency looked again at the safety of Micotil, following a request by the European Commission to take into account new information. 
Agencija je spet preučila varnost Micotila, potem ko je Evropska komisija zahtevala, naj se upoštevajo nove informacije.
Fee exemptions for certain administrative services of the EMEA 
oprostitve pristojbin za določene administrativne storitve EMEA;
It provided support to the European Commission with the technical requirements for such products, and will continue to do so as necessary during the Council and European Parliament consultation process. 
Evropski komisiji je zagotovila podporo s tehničnimi zahtevami za takšne izdelke in bo po potrebi še naprej zagotavljala podporo med postopkom posvetovanja med Svetom in Evropskim parlamentom.
Thanks to the excellent planning and preparations put in place during the run-up to that date, the Agency was able to successfully implement all relevant provisions and guidelines stemming from the new legislation. 
Zahvaljujoč izvrstnemu načrtovanju in pripravam v obdobju pred tem datumom, je Agenciji uspelo uspešno izvesti vse zadevne določbe in smernice, ki izhajajo iz nove zakonodaje.
A total of 1,213 applications were received, which represents a 10% increase compared to 2004. 
Prejetih je bilo skupno 1213 vlog, kar pomeni 10-odstotno povečanje v primerjavi z letom 2004.
On behalf of the Management Board, therefore, I would like to thank the personnel of the EMEA for their important input in promoting European regulation in the field of pharmaceuticals. 
V imenu upravnega odbora bi se zato rad zahvalil osebju EMEA za njihov pomemben prispevek k spodbujanju evropske regulacije na farmacevtskem področju.
Lastly, I extend my wholehearted thanks to all EMEA staff, whose tireless efforts throughout this challenging year resulted in such a positive outcome for the Agency. 
Na koncu pa se iz vsega srca zahvaljujem tudi celotnemu osebju EMEA, katerega neutrudni napori skozi vse to leto, polno izzivov, so doprinesli k tako pozitivnim rezultatom Agencije.
The Committee concluded in November 2005 that, based on the available evidence, no action to protect consumer safety or animal safety was necessary. 
Novembra 2005 je Odbor sklenil, da na podlagi razpoložljivih dokazov niso potrebni nobeni ukrepi za zaščito varnosti potrošnikov ali živali.
The recommendations were the outcome of an extensive external consultation exercise with the Agency's partners and stakeholders. 
Priporočila so bila rezultat obsežnih zunanjih posvetovanj s partnerji Agencije in zainteresiranimi stranmi.
The SME Office has the sole remit of offering assistance to SMEs. 
Urad za MSP je pristojen samo za zagotavljanje pomoči malim in srednje velikim podjetjem.
The Committee focused on work to establish the necessary procedures for conducting its business. 
Odbor je namenil glavno pozornost pripravam za določitev potrebnih postopkov za opravljanje svoje dejavnosti.
3.2.3 Maximum residue limits 
3.2.3 Najvišje mejne vrednosti ostankov
Those ten years of continuous growth and consolidation gave the Agency the experience and confidence it needed to meet the greatest challenge it has had to face so far: the full entry into force of the revised EU pharmaceutical legislation, in November 2005. 
Teh deset let nenehne rasti in utrjevanja je dalo Agenciji izkušnje in zaupanje , ki ju potrebuje, da se bo lahko spopadla s svojim največjim izzivom doslej: novembra 2005 bo namreč v celoti stopila v veljavo revidirana farmacevtska zakonodaja EU.
9 INFORMATION AND COMMUNICATION 
9 OBVEŠČANJE IN KOMUNICIRANJE
I know I can rely on your continuing commitment as we bring the EMEA forward into its second decade. 
Vem, da se lahko na vašo nadaljnjo zavezanost zanesem tudi zdaj, ko EMEA stopa v svoje drugo desetletje.
A special group (ERMS facilitation group) was set up to oversee the delivery of these key objectives through the development of a rolling work plan for 2005-2007. 
Ustanovljena je bila posebna skupina (skupina za poenostavitev ERMS) za nadzor izpolnjevanja teh ključnih ciljev s pomočjo razvoja tekočega načrta dela za obdobje 2005-2007.
The Year 2005 was a very promising beginning for the second decade of the EMEA. 
Leto 2005 je bil zelo obetaven začetek drugega desetletja delovanja EMEA.
Altogether, 238 deaths in animals were reported. 
Prijavljenih je bilo skupaj 238 smrtnih primerov pri živalih.